Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026. About Oruka Therapeutics Oruka Therapeutics is dev
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Covered in this story
What has happened since
- Morgan Stanley is down 14.6% since this was published, 43 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ORKA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Oruka Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.